Literature DB >> 6572905

Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth.

T F Bumol, Q C Wang, R A Reisfeld, N O Kaplan.   

Abstract

A monoclonal antibody directed against a cell surface chondroitin sulfate proteoglycan of human melanoma cells, 9.2.27, and its diphtheria toxin A chain (DTA) conjugate were investigated for their effects on in vitro protein synthesis and in vivo tumor growth of human melanoma cells. The 9.2.27 IgG and its DTA conjugate display similar serological activities against melanoma target cells but only the conjugate can induce consistent in vitro inhibition of protein synthesis and toxicity in M21 melanoma cells. However, both 9.2.27 IgG and its DTA conjugate effect significant suppression of M21 tumor growth in vivo in an immunotherapy model of a rapidly growing tumor in athymic nu/nu mice, suggesting that other host mechanisms may mediate monoclonal antibody-induced tumor suppression.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572905      PMCID: PMC393412          DOI: 10.1073/pnas.80.2.529

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  A reporter group delivery system with both absolute and selective specificity for thiol groups and an improved fluorescent probe containing the 7-nitrobenzo-2-oxa-1,3-diazole moiety.

Authors:  T Stuchbury; M Shipton; R Norris; J P Malthouse; K Brocklehurst; J A Herbert; H Suschitzky
Journal:  Biochem J       Date:  1975-11       Impact factor: 3.857

Review 3.  Glycosaminoglycans and their binding to biological macromolecules.

Authors:  U Lindahl; M Höök
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

4.  Physiological function of connective tissue polysaccharides.

Authors:  W D Comper; T C Laurent
Journal:  Physiol Rev       Date:  1978-01       Impact factor: 37.312

5.  Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis.

Authors:  T Honjo; Y Nishizuka; O Hayaishi
Journal:  J Biol Chem       Date:  1968-06-25       Impact factor: 5.157

6.  Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.

Authors:  D O Chee; A W Boddie; J A Roth; E C Holmes; D L Morton
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

7.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.

Authors:  R G Woodbury; J P Brown; M Y Yeh; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

8.  Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab')2 fragment.

Authors:  W C Ross; P E Thorpe; A J Cumber; D C Edwards; C A Hinson; A J Davies
Journal:  Eur J Biochem       Date:  1980-03

9.  Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

Authors:  I D Bernstein; M R Tam; R C Nowinski
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

10.  Study of antibodies against human melanoma produced by somatic cell hybrids.

Authors:  H Koprowski; Z Steplewski; D Herlyn; M Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

View more
  27 in total

1.  Recombinant DNA technology for melanoma immunotherapy: anti-Id DNA vaccines targeting high molecular weight melanoma-associated antigen.

Authors:  A Barucca; M Capitani; M Cesca; D Tomassoni; U Kazmi; F Concetti; L Vincenzetti; A Concetti; F M Venanzi
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

Review 2.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Authors:  F Buchegger; C Pfister; K Fournier; F Prevel; M Schreyer; S Carrel; J P Mach
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

4.  Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Authors:  G Schulz; T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

Review 5.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen.

Authors:  K Imai; T Nakanishi; T Noguchi; A Yachi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

Authors:  G M Stuhlmiller; T L Darrow; D M Haupt; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen.

Authors:  T Ghose; S Ferrone; A H Blair; Y Kralovec; M Temponi; M Singh; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.

Authors:  H M Yang; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

10.  An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain.

Authors:  S A Eccles; D P McIntosh; H P Purvies; A J Cumber; G D Parnell; J A Forrester; J M Styles; C J Dean
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.